August 8, 2017 Shenzhen, China. Amoy Diagnostics Co., Ltd. (AmoyDx), a Xiamen-based biotechnology firm became a public company on August 2, 2017 with ShenZhen Stock Exchange (SZSE) code 300685 and began trading on SZSE the same day. The fund raised will be invested on new products & technologies' development, R&D Center expansion and construction of marketing & sales information system, which are dedicated to providing better products and services to our clients and patients.
AmoyDx is the pioneer in leading the technology development and industrialization of molecular diagnostics of oncology precision medicine in China. We are the biggest provider of oncology molecular diagnostic products in China, covering most of the top-tier hospitals. Meanwhile we have built up partnership and cooperation with some multinational pharmaceutical companies and provided products and services to various customers in over 50 countries worldwide.
For more information about AmoyDx, please visit www.amoydx.com
AmoyDx is the pioneer in leading the technology development and industrialization of molecular diagnostics of oncology precision medicine in China. We are the biggest provider of oncology molecular diagnostic products in China, covering most of the top-tier hospitals. Meanwhile we have built up partnership and cooperation with some multinational pharmaceutical companies and provided products and services to various customers in over 50 countries worldwide.
For more information about AmoyDx, please visit www.amoydx.com
